Published in Biochemistry on May 02, 1989
DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev (1997) 9.69
Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli. Antimicrob Agents Chemother (1991) 6.19
DNA gyrase gyrA mutations in ciprofloxacin-resistant strains of Staphylococcus aureus: close similarity with quinolone resistance mutations in Escherichia coli. J Bacteriol (1990) 5.13
4-Quinolone resistance mutations in the DNA gyrase of Escherichia coli clinical isolates identified by using the polymerase chain reaction. Antimicrob Agents Chemother (1991) 4.35
Interaction of the plasmid-encoded quinolone resistance protein Qnr with Escherichia coli DNA gyrase. Antimicrob Agents Chemother (2005) 4.03
A single point mutation in the DNA gyrase A protein greatly reduces binding of fluoroquinolones to the gyrase-DNA complex. Antimicrob Agents Chemother (1993) 3.43
Association between double mutation in gyrA gene of ciprofloxacin-resistant clinical isolates of Escherichia coli and MICs. Antimicrob Agents Chemother (1994) 2.87
Novel quinolone resistance mutations of the Escherichia coli DNA gyrase A protein: enzymatic analysis of the mutant proteins. Antimicrob Agents Chemother (1991) 2.82
Mechanism of action of quinolones against Escherichia coli DNA gyrase. Antimicrob Agents Chemother (1993) 2.48
Analysis by PCR and direct DNA sequencing of gyrA mutations associated with fluoroquinolone resistance in Enterococcus faecalis. Antimicrob Agents Chemother (1994) 2.43
Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases. Nat Struct Mol Biol (2009) 2.05
Contribution of the C-8 substituent of DU-6859a, a new potent fluoroquinolone, to its activity against DNA gyrase mutants of Pseudomonas aeruginosa. Antimicrob Agents Chemother (1995) 1.84
Novel gyrA point mutation in a strain of Escherichia coli resistant to fluoroquinolones but not to nalidixic acid. Antimicrob Agents Chemother (1993) 1.73
Transport of pefloxacin across the bacterial cytoplasmic membrane in quinolone-susceptible Staphylococcus aureus. Antimicrob Agents Chemother (1992) 1.62
Active efflux of fluoroquinolones in Mycobacterium smegmatis mediated by LfrA, a multidrug efflux pump. J Bacteriol (1996) 1.50
Correlation of quinolone MIC and inhibition of DNA, RNA, and protein synthesis and induction of the SOS response in Escherichia coli. Antimicrob Agents Chemother (1990) 1.46
Quinolone mode of action. Drugs (1995) 1.44
Incidence of various gyrA mutants in 451 Staphylococcus aureus strains isolated in Japan and their susceptibilities to 10 fluoroquinolones. Antimicrob Agents Chemother (1995) 1.44
Mechanisms of resistance to quinolones. Drugs (1993) 1.41
Discovery and development of new antibiotics: the problem of antibiotic resistance. Antimicrob Agents Chemother (1993) 1.41
Characterization of mutations in Mycobacterium smegmatis involved in resistance to fluoroquinolones. Antimicrob Agents Chemother (1994) 1.27
Engineering the specificity of antibacterial fluoroquinolones: benzenesulfonamide modifications at C-7 of ciprofloxacin change its primary target in Streptococcus pneumoniae from topoisomerase IV to gyrase. Antimicrob Agents Chemother (2000) 1.25
Mechanism of action of and resistance to quinolones. Microb Biotechnol (2008) 1.16
Effect of magnesium complexation by fluoroquinolones on their antibacterial properties. Antimicrob Agents Chemother (1994) 1.15
Effect of aerobic and anaerobic environments on antistaphylococcal activities of five fluoroquinolones. Antimicrob Agents Chemother (1995) 1.14
Quinolone binding to DNA is mediated by magnesium ions. Proc Natl Acad Sci U S A (1992) 1.10
Mechanism of differential activities of ofloxacin enantiomers. Antimicrob Agents Chemother (1996) 1.07
Significance of the methyl group on the oxazine ring of ofloxacin derivatives in the inhibition of bacterial and mammalian type II topoisomerases. Antimicrob Agents Chemother (1991) 1.07
Localization of an aminoacridine antitumor agent in a type II topoisomerase-DNA complex. Proc Natl Acad Sci U S A (1994) 1.06
Mutational analysis of a type II topoisomerase cleavage site: distinct requirements for enzyme and inhibitors. EMBO J (1993) 1.01
In vitro assays used to measure the activity of topoisomerases. Antimicrob Agents Chemother (1990) 0.98
Drug features that contribute to the activity of quinolones against mammalian topoisomerase II and cultured cells: correlation between enhancement of enzyme-mediated DNA cleavage in vitro and cytotoxic potential. Antimicrob Agents Chemother (1993) 0.97
Antibacterial activities and inhibitory effects of sitafloxacin (DU-6859a) and its optical isomers against type II topoisomerases. Antimicrob Agents Chemother (1998) 0.95
New anti-human immunodeficiency virus type 1 6-aminoquinolones: mechanism of action. Antimicrob Agents Chemother (2003) 0.94
Effect of pyrimido[1,6-a]benzimidazoles, quinolones, and Ca2+ on the DNA gyrase-mediated cleavage reaction. Antimicrob Agents Chemother (1995) 0.93
Biological characterization of cyclothialidine, a new DNA gyrase inhibitor. Antimicrob Agents Chemother (1993) 0.92
Effects of ciprofloxacin on plasmid DNA supercoiling of Escherichia coli topoisomerase I and gyrase mutants. Antimicrob Agents Chemother (1991) 0.92
Effect of emergence of fluoroquinolone resistance on intrinsic expression of P-glycoprotein phenotype in corneal epithelial cells. J Ocul Pharmacol Ther (2011) 0.91
Ciprofloxacin dimers target gyrase in Streptococcus pneumoniae. Antimicrob Agents Chemother (2004) 0.90
Antibiotic treatment enhances the genome-wide mutation rate of target cells. Proc Natl Acad Sci U S A (2016) 0.90
Quinolone-DNA interaction: sequence-dependent binding to single-stranded DNA reflects the interaction within the gyrase-DNA complex. Antimicrob Agents Chemother (2003) 0.88
Mechanism of inhibition of DNA gyrase by cyclothialidine, a novel DNA gyrase inhibitor. Antimicrob Agents Chemother (1994) 0.88
Topoisomerase II-mediated site-directed alkylation of DNA by psorospermin and its use in mapping other topoisomerase II poison binding sites. Proc Natl Acad Sci U S A (1998) 0.87
Molecular basis for the differential quinolone susceptibility of mycobacterial DNA gyrase. Antimicrob Agents Chemother (2014) 0.81
Mechanism of action of a novel series of naphthyridine-type ribosome inhibitors: enhancement of tRNA footprinting at the decoding site of 16S rRNA. Antimicrob Agents Chemother (2005) 0.80
Synthesis of ciprofloxacin-conjugated poly (L-lactic acid) polymer for nanofiber fabrication and antibacterial evaluation. Int J Nanomedicine (2014) 0.79
Alarmingly High Segregation Frequencies of Quinolone Resistance Alleles within Human and Animal Microbiomes Are Not Explained by Direct Clinical Antibiotic Exposure. Genome Biol Evol (2015) 0.78
miR-144 functions as a tumor suppressor in breast cancer through inhibiting ZEB1/2-mediated epithelial mesenchymal transition process. Onco Targets Ther (2016) 0.76
Molecular details of quinolone-DNA interactions: solution structure of an unusually stable DNA duplex with covalently linked nalidixic acid residues and non-covalent complexes derived from it. Nucleic Acids Res (2005) 0.76
Synthesis, characterization, and biological activity studies of copper(II) mixed compound with histamine and nalidixic acid. Bioinorg Chem Appl (2009) 0.75
Synthesis and Study of Some New Quinolone Derivatives Containing a 3-acetyl Coumarin for Their Antibacterial and Antifungal Activities. Iran J Pharm Res (2017) 0.75
Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature (1984) 5.85
The Heidelberg classification of renal cell tumours. J Pathol (1997) 5.36
Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene (2007) 4.81
Mechanism of met oncogene activation. Cell (1986) 4.20
Mechanism of inhibition of DNA gyrase by analogues of nalidixic acid: the target of the drugs is DNA. Proc Natl Acad Sci U S A (1985) 3.18
Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. Nat Genet (1994) 3.10
Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene (2006) 3.09
Tyrosine kinase receptor indistinguishable from the c-met protein. Nature (1989) 3.00
Complex patterns of ETS gene alteration arise during cancer development in the human prostate. Oncogene (2007) 2.68
The t(X;1)(p11.2;q21.2) translocation in papillary renal cell carcinoma fuses a novel gene PRCC to the TFE3 transcription factor gene. Hum Mol Genet (1996) 2.45
Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer (2010) 2.45
Instability of short tandem repeats (microsatellites) in human cancers. Nat Genet (1994) 2.45
Predictors of laparoscopic complications after formal training in laparoscopic surgery. JAMA (1993) 2.37
Dog, cat, and human bites: a review. J Am Acad Dermatol (1995) 2.35
Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma. Oncogene (1997) 2.32
Localization to Xq27 of a susceptibility gene for testicular germ-cell tumours. Nat Genet (2000) 2.26
Nonvenereal treponematoses: yaws, endemic syphilis, and pinta. J Am Acad Dermatol (1993) 2.22
Chromosome mediated gene transfer of six DNA markers linked to the cystic fibrosis locus on human chromosome seven. Nucleic Acids Res (1986) 2.16
Fusion of SYT to two genes, SSX1 and SSX2, encoding proteins with homology to the Kruppel-associated box in human synovial sarcoma. EMBO J (1995) 2.14
Biosynthesis of the protein encoded by the c-met proto-oncogene. Oncogene (1989) 1.92
New method for detecting cellular transforming genes. Science (1982) 1.92
In vitro susceptibility of Coxiella burnetii to antibiotics, including several quinolones. Antimicrob Agents Chemother (1987) 1.82
Misidentified cell. Nature (1989) 1.81
Telomerase repressor sequences on chromosome 3 and induction of permanent growth arrest in human breast cancer cells. J Natl Cancer Inst (1999) 1.73
Detection of point mutations in N-ras and K-ras genes of human embryonal rhabdomyosarcomas using oligonucleotide probes and the polymerase chain reaction. Cancer Res (1989) 1.64
Mechanism of inhibition of DNA gyrase by quinolone antibacterials: specificity and cooperativity of drug binding to DNA. Biochemistry (1989) 1.63
Search for chromosomal variations among gas-exposed persons in Bhopal. Hum Genet (1990) 1.62
Cutaneous metastases. Med Clin North Am (1980) 1.61
An activated rasN gene: detected in late but not early passage human PA1 teratocarcinoma cells. Science (1984) 1.56
Tpr, a large coiled coil protein whose amino terminus is involved in activation of oncogenic kinases, is localized to the cytoplasmic surface of the nuclear pore complex. J Cell Biol (1994) 1.52
Appendicovesicostomy: the mitrofanoff procedure-a 15-year perspective. J Urol (2000) 1.50
Expression analysis onto microarrays of randomly selected cDNA clones highlights HOXB13 as a marker of human prostate cancer. Br J Cancer (2005) 1.46
Chronically and acutely exercised rats: biomarkers of oxidative stress and endogenous antioxidants. J Appl Physiol (1985) (2000) 1.45
Pharmacokinetics of temafloxacin in humans after single oral doses. Antimicrob Agents Chemother (1991) 1.43
The 2-pyridone antibacterial agents: bacterial topoisomerase inhibitors. Med Res Rev (2000) 1.38
Antimicrobial agents from higher plants. Antimicrobial agents from Peganum harmala seeds. J Nat Prod (1982) 1.38
Shipboard medicine: a new niche for emergency medicine. Ann Emerg Med (1992) 1.38
Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer. Br J Cancer (2008) 1.37
Fortimicins A and B, new aminoglycoside antibiotics. III. Structural identification. J Antibiot (Tokyo) (1977) 1.37
Antimicrobial agents from higher plants. I. Introduction, rationale, and methodology. Lloydia (1972) 1.35
Characterization of the human cell line TE671. Carcinogenesis (1989) 1.34
Novel halogenated sulfonamides inhibit the growth of multidrug resistant MCF-7/ADR cancer cells. Bioorg Med Chem Lett (1999) 1.34
Selective, covalent modification of beta-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors. Proc Natl Acad Sci U S A (1999) 1.33
Expression profile of genes from 12p in testicular germ cell tumors of adolescents and adults associated with i(12p) and amplification at 12p11.2-p12.1. Oncogene (2003) 1.32
Characterization of the mouse met proto-oncogene. Oncogene (1988) 1.31
Functional domains of the SYT and SYT-SSX synovial sarcoma translocation proteins and co-localization with the SNF protein BRM in the nucleus. Hum Mol Genet (1999) 1.31
Amplification and overexpression of the met gene in spontaneously transformed NIH3T3 mouse fibroblasts. EMBO J (1986) 1.28
Pharmacology of CP-99,994; a nonpeptide antagonist of the tachykinin neurokinin-1 receptor. J Pharmacol Exp Ther (1993) 1.26
Role of E2F3 expression in modulating cellular proliferation rate in human bladder and prostate cancer cells. Oncogene (2006) 1.24
Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer. Br J Cancer (2013) 1.23
Structure-activity relationships among DNA gyrase inhibitors. Synthesis and biological evaluation of 1,2-dihydro-4, 4-dimethyl-1-oxo-2-naphthalenecarboxylic acids as 1-carba bioisosteres of oxolinic acid. J Med Chem (1984) 1.19
The human SB1.8 gene (DXS423E) encodes a putative chromosome segregation protein conserved in lower eukaryotes and prokaryotes. Hum Mol Genet (1995) 1.17
Fusion of the EWS gene to CHN, a member of the steroid/thyroid receptor gene superfamily, in a human myxoid chondrosarcoma. Oncogene (1996) 1.17
Characterization of human transforming genes from chemically transformed, teratocarcinoma, and pancreatic carcinoma cell lines. Cancer Res (1984) 1.17
Antimicrobial agents from higher plants. An investigation of Hunnemannia fumariaefolia pseudoalcoholates of sanguinarine and chelerythrine. Lloydia (1978) 1.15
The human tpr gene encodes a protein of 2094 amino acids that has extensive coiled-coil regions and an acidic C-terminal domain. Oncogene (1992) 1.14
Effect of cigarette smoking on sputum smear conversion in adults with active pulmonary tuberculosis. Respir Med (2005) 1.14
TEAD1 and c-Cbl are novel prostate basal cell markers that correlate with poor clinical outcome in prostate cancer. Br J Cancer (2008) 1.13
Conservative management of cystic dysplasia of the testis. J Urol (1999) 1.11
Keratoacanthomas arising within a linear epidermal nevus. J Dermatol Surg Oncol (1982) 1.09
Evidence that a low-fat diet reduces the occurrence of non-melanoma skin cancer. Int J Cancer (1995) 1.09
Molecular classification of synovial sarcomas, leiomyosarcomas and malignant fibrous histiocytomas by gene expression profiling. Br J Cancer (2003) 1.08
Early developmental changes in [3H]nicotine binding in the human brainstem. Neuroscience (1993) 1.08
Processing of radical prostatectomy specimens for correlation of data from histopathological, molecular biological, and radiological studies: a new whole organ technique. J Clin Pathol (2005) 1.08
Biopsy tissue microarray study of Ki-67 expression in untreated, localized prostate cancer managed by active surveillance. Prostate Cancer Prostatic Dis (2008) 1.07
Metastatic squamous cell carcinoma of the lip. Occurrence in blacks with discoid lupus erythematosus. Arch Dermatol (1979) 1.07
Variables associated with disrupted placement in a select sample of abused and neglected children. Child Abuse Negl (1987) 1.06
LUCA-15-encoded sequence variants regulate CD95-mediated apoptosis. Oncogene (2000) 1.06
Pigmented Bowen's disease (squamous cell carcinoma in situ): a mimic of malignant melanoma. Dermatol Surg (2001) 1.06
Construction of tissue microarrays from prostate needle biopsy specimens. Br J Cancer (2005) 1.05
Detection of growth hormone abuse in sport. Growth Horm IGF Res (2007) 1.05
Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangement. Br J Cancer (2009) 1.04
Abnormalities of the p53 MDM2 and DCC genes in human leiomyosarcomas. Br J Cancer (1994) 1.03
The activated human met gene encodes a protein tyrosine kinase. FEBS Lett (1986) 1.03
Substituted 5,6-dihydrofuro[3,2-f]-1,2-benzisoxazole-6-carboxylic acids: high-ceiling diuretics with uricosuric activity. J Med Chem (1984) 1.03
Primary structure of the met protein tyrosine kinase domain. Oncogene (1987) 1.02
Nucleotide sequence analysis of human tpr cDNA clones. Oncogene (1992) 1.02
Prevalence and pattern of drug abuse among Delhi University students. Indian J Med Res (1977) 1.01
Impulse oscillometry: an alternative modality to the conventional pulmonary function test to categorise obstructive pulmonary disorders. Clin Exp Med (2007) 1.01
Synthesis and structure-activity relationships of novel arylfluoroquinolone antibacterial agents. J Med Chem (1985) 1.01
Structure of the met protein and variation of met protein kinase activity among human tumour cell lines. Br J Cancer (1988) 1.01
Effect of a low-fat diet on the incidence of actinic keratosis. N Engl J Med (1994) 1.00
The structural characterization of tetrangomycin and tetrangulol. J Org Chem (1966) 1.00
Rapid screening of natural products for antimycobacterial activity by using luciferase-expressing strains of Mycobacterium bovis BCG and Mycobacterium intracellulare. Antimicrob Agents Chemother (1997) 0.99
Quinolone antimicrobial agents. 2. Methylenedioxy positional isomers of oxolinic acid. J Med Chem (1979) 0.99
Granuloma inguinale. J Am Acad Dermatol (1984) 0.98
Plasma apolipoprotein A-I and B concentrations in growth-retarded fetuses: a link between low birth weight and adult atherosclerosis. J Clin Endocrinol Metab (2000) 0.98
Synthesis and structure-activity relationships of 2-pyridones: a novel series of potent DNA gyrase inhibitors as antibacterial agents. J Med Chem (1996) 0.97
Inactivation of a diol epoxide by dihydrodiol dehydrogenase but not by two epoxide hydrolases. Science (1982) 0.96
Percutaneous cholecystostomy for the treatment of acute cholecystitis in the critically ill and elderly. Hong Kong Med J (2004) 0.96
Structures of LL-AC541 and LL-AB664: new streptothricin-type antibiotics. Tetrahedron (1970) 0.96
PRCC, the commonest TFE3 fusion partner in papillary renal carcinoma is associated with pre-mRNA splicing factors. Oncogene (2001) 0.95
Mapping the X chromosome breakpoint in two papillary renal cell carcinoma cell lines with a t(X;1)(p11.2;q21.2) and the first report of a female case. Cytogenet Cell Genet (1995) 0.95
LL-A491, a monazomycin-like antibiotic. Appl Microbiol (1967) 0.95
Laparoscopic nephrectomy of a horseshoe kidney. J Endourol (1997) 0.95
Localised genital Norwegian scabies in an AIDS patient. Sex Transm Infect (2004) 0.94